These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6113735)

  • 1. Oral versus depot medication in schizophrenia.
    Johnson DA
    Acta Psychiatr Scand Suppl; 1981; 291():56-64. PubMed ID: 6113735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term depot antipsychotics. A risk-benefit assessment.
    Barnes TR; Curson DA
    Drug Saf; 1994 Jun; 10(6):464-79. PubMed ID: 7917075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM; Kane JM
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations on the use of depot neuroleptics in schizophrenia.
    Johnson DA
    Psychopharmacol Ser; 1988; 5():62-72. PubMed ID: 2901084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 7. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
    Stanković Z; Ille T
    Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The significance of depot medication in the long-term-treatment of schizophrenia].
    Kühn KU; Wiedemann K; Hellweg R; Möller HJ
    Fortschr Neurol Psychiatr; 2014 Oct; 82(10):557-65. PubMed ID: 25299626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depot neuroleptics: side effects and safety.
    Marder SR
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):24S-29S. PubMed ID: 2870089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
    Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
    J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.
    Kirson NY; Weiden PJ; Yermakov S; Huang W; Samuelson T; Offord SJ; Greenberg PE; Wong BJ
    J Clin Psychiatry; 2013 Jun; 74(6):568-75. PubMed ID: 23842008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of depot medications in the treatment of schizophrenia.
    Davis JM
    Am J Psychiatry; 2010 Feb; 167(2):125-6. PubMed ID: 20123919
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effects and side effects of depot neuroleptics as perceived by patients].
    Trenckmann U
    Psychiatr Prax; 1990 Sep; 17(5):184-7. PubMed ID: 1980015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.
    Adams CE; Fenton MK; Quraishi S; David AS
    Br J Psychiatry; 2001 Oct; 179():290-9. PubMed ID: 11581108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The attitude of patients towards antipsychotic depot treatment.
    Heres S; Schmitz FS; Leucht S; Pajonk FG
    Int Clin Psychopharmacol; 2007 Sep; 22(5):275-82. PubMed ID: 17690596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives.
    Möller HJ
    Drugs; 2007; 67(11):1541-66. PubMed ID: 17661527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.